Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial

British Journal of Cancer · Published 2026-06-23 · DOI 10.1038/s41416-026-03511-0

Free full text

Authors (17)

Jiajia Yuan, Jifang Gong, Zhi Peng, Tian Shu Liu, HuiTing Xu, Jianwei Yang, Jia Wei, Haiping Jiang, Yanhong Deng, Yusheng Wang, Changsong Qi, Cheng Lyu, Qiao Sun, Lei Mu, Lin Song, Xiaotian Zhang, Lin Shen

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Yuan, J., Gong, J., Peng, Z., et al. (2026). Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03511-0

Related articles